SiMa, a new neuroblastoma cell line combining poor prognostic cytogenetic markers with high adrenergic differentiation.
We describe the establishment and characterization of a new neuroblastoma (Nb) cell line, SiMa, carrying the major recurrent chromosome changes associated with poor prognosis Nb, including amplification of N-MYC by formation of double minutes (dmin), der(1)t(1;17)(p35;q12) and der(22)t(17;22)(q22;p13), and loss of chromosome 11, documented at both initiation and late passage. In contrast to these cytogenetic stigmata of poor prognosis, analysis of catecholamine synthesis by high pressure liquid chromatography (HPLC) measurement revealed an advanced degree of adrenergic differentiation with high rates of 3,4-Dihydroxyphenylalanine (DOPA), noradrenaline, homovanillic acid (HVA), and vanillylmandelic acid (VMA) production. Contrastingly advanced differentiation and poor prognostic genetic markers combine to render SiMa a unique instrument for investigating the pathology and therapy of Nb.
Marini
P
P
Department of Pediatric Surgery, Klinikum Schnarrenberg, University of Tuebingen, Germany.
MacLeod
R A
RA
Treuner
C
C
Bruchelt
G
G
Böhm
W
W
Wolburg
H
H
Schweizer
P
P
Girgert
R
R
D002454:Cell Differentiation / Q000502:physiology*; D002869:Chromosome Aberrations; D004837:Epinephrine / Q000502:physiology*; D005819:Genetic Markers; D006801:Humans; D017404:In Situ Hybridization, Fluorescence; D007223:Infant; D007621:Karyotyping; D008297:Male; D009447:Neuroblastoma / Q000235:genetics* / Q000473:pathology; D011379:Prognosis; D014407:Tumor Cells, Cultured
D005819:Genetic Markers; D004837:Epinephrine